LOGO AHF

BIOGRAPHICAL INFORMATION

1. Your Email *

(This will only be used for the purpose of this survey and to send you the final report).


2. Country *

3. Specialty *

4. Subspecialty *

5. Type of Health Institution where you work: *

6. Name of Medical Center or Institution where you work: *

7. Estimated number of new cases of cancer seen per month *

Please fill with number

DISRUPTION OF CANCER CARE

8. A) To what level has the usual patient care at your center been affected by the Covid-19 pandemic? *

8. B) Please order these from most impactful to least impactful reason patient care been affected by the pandemic. Drag and drop each answer in order with the top most being the most impactful reason. *
  • 1) Precautionary measures (i.e., government and public health regulations)
  • 2) Overwhelmed health system
  • 3) Staff shortage due to COVID-19 diagnosis or reassignment to other areas
  • 4) Lack of access to medications
  • 5) Quarantine/Travel bans
  • 6) Other (i.e., patients fear of COVID-19)

9. A) Did the treatment center you work close at any time during the COVID-19 pandemic? *

9. B) In what areas was there disruption? *
No Mild Moderate Severe N/A
Surgery
Radiation therapy
Chemotherapy
Immunotherapy
Hormone therapy
Target therapy
Stem cell transplant
Palliative care
Supportive care i.e. nutrition, rehabilitation, psychological care etc.
Diagnostics

Surgery

Radiation therapy

Chemotherapy

Immunotherapy

Hormone therapy

Target therapy

Stem cell transplant

Palliative care

Supportive care i.e. nutrition, rehabilitation, psychological care etc.

Diagnostics

EPIDEMIOLOGICAL TRENDS

10. A) Have you perceived a change in new cases of cancer in the first 6 months of the pandemic? (March 2020-August 2020) *
0% 0-25%% 26-50% 51-75% > 75% N/A
If increased, how much?
If decreased, how much?

If increased, how much?

If decreased, how much?

10. B) Have you perceived a change in new cases of cancer in the last 6 months of the pandemic? (September 2020-February 2021)? *
0% 0-25%% 26-50% 51-75% > 75% N/A
If increased, how much?
If decreased, how much?

If increased, how much?

If decreased, how much?

11. Have you perceived delays in cancer diagnosis due to the pandemic? *

12. Of the cases you diagnose in a TYPICAL year (pre-pandemic), how are they distributed by clinical stage at time of diagnosis? Please provide a specific percentage for each stage (the percentages should sum up to 100%) for each the cancer(s) that you provide care for. (Lung, Breast, Colorectal, Prostate, Cervical) *

Cancer Type: Stage I ___ % Stage II ___ % Stage III ___ % Stage IV ___ %
eg answer 1: Breast: 20,30,50,0 =100%
eg answer 2: Cervical: 10,20,50,20 =100%
Lung: 30,10,20,40 =100%

13. A) Have you perceived an increase in advanced disease at time of diagnosis due to the pandemic? *

13. A.1) If yes, please mark all that apply. *
0-10% 11-25% 26-50% 51-75% > 75% N/A
Breast Cancer: In how many patients
Colorectal Cancer: In how many patients ?
Cervical Cancer: In how many patients ?
Prostate Cancer: In how many patients ?
Lung Cancer: In how many patients ?

Breast Cancer: In how many patients

Colorectal Cancer: In how many patients ?

Cervical Cancer: In how many patients ?

Prostate Cancer: In how many patients ?

Lung Cancer: In how many patients ?

14. Have you noticed an increase in cancer mortality because of the pandemic? *

15. Have you seen an increase in relapses? *

SCREENING AND PREVENTION

16. Have you noticed a decrease in the number of cancer screening tests? *
0% 0%-10% 11-%25% 26%-50% 51%-75% >75% N/A
Mammography
Colonoscopy
PSA test
CT of thorax
Biopsy / Pathology

Mammography

Colonoscopy

PSA test

CT of thorax

Biopsy / Pathology

17. If there was prevention program in place for the cancer before the pandemic, has it been affected? *

OUTPATIENT CLINIC VISITS

18. How has the pandemic affected outpatient clinic visits? *

19. Do you think virtual clinic visits will continue after the pandemic? *

20. Have patients sought treatment in a different center due to interruptions or closures? (i.e. in larger cities or higher complexity) *

21. Have you increased the time between follow-up visits for patients? *

22. Because of the pandemic, have cancer patients been given the option to have laboratory tests performed at a laboratory close to their homes? *

23. Were tumor boards available at your center before the pandemic? *

23. A) If yes, what has been the impact of the pandemic on tumor boards? *

23. B) Do you forsee that virtual tumor boards will persist after the pandemic? *

TREATMENT CHANGES

24. A) Have your patients experienced treatment interruptions in 2020 (March-December) because of the pandemic? *

24. A.1) If yes, how long do these interruptions last on average? *

25. A) Have your patients experienced treatment interruptions in 2021 (January-May) because of the pandemic?

25. A.1) If yes, how long do these interruptions last on average? *

26. What is the percentage of the patients who abandoned therapy during COVID 19 pandemic? *

26. A) What is the main reason for abandoning therapy? *

27. Because of the pandemic, have cancer patients been given the option to have their medications delivered to their homes? *

28. In how many patients have you reduced doses of cancer chemotherapy treatment as a result of the pandemic? *

29. What percentage of your patients missed at least one planned cancer chemotherapy treatment cycle during COVID-19 pandemic? *

30. In how many patients did you change any part of your patient’s treatment due to the pandemic? *

31. Have you reduced your use of G-CSF during chemotherapy regimens due to the pandemic? *

32. A) In how many patients have you used more oral agents instead of IV therapy during the pandemic, when they are available? *

32. A.1) Do your patients face access barriers to oral agents? *

33. Due to COVID-19, have you had to deviate from clinical practice guidelines or standard of care by postponing surgery when it was indicated? In how many patients? *

34. Due to COVID-19, have you had to deviate from clinical practice guidelines or standard of care by postponing radiotherapy when it was indicated? In how many patients? *

35. Have you perceived potential harm to patients due to interruptions in care due to COVID-19 care? *

COVID-19 DIAGNOSIS AND CONTROL IN ONCOLOGY

36. Have you seen oncologic patients with a COVID-19 diagnosis? Out-patients (Not hospitalized). *

37. Have you seen oncologic patients with a COVID-19 diagnosis? In-patients (Hospitalized). *

38. Has there been a shortage of PPE in your center for your practice? (Please mark all that apply). *

39. Have any staff of your oncology team been diagnosed with COVID-19? *

40. Have you recommended vaccination for the majority of your oncologic patients? *

41. When was vaccination made available for cancer patients in your city? *

ECONOMIC IMPACT QUESTIONS

42. Have you been asked by your institution or insurance companies to implement cost-containment measures in their delivery of cancer care? *

43. Have you seen changes in the budget allocated to cancer care in you center? *

44. During the pandemic, have there been changes in resources allocation to cancer care by your government (Public spending for cancer)? *

45. A) After the pandemic, do you expect to see an overflow of cancer patients (Including patients that were unable to consult previously, awaiting oncologic consultations, or with disease progression due to delays in treatment initiation)? *

45. A.1) If yes, in your opinion, will your country’s healthcare system be prepared for this increase in terms of: *
Very Prepared Moderately Prepared Mildly Prepared Not Prepared N/A
Budget allocation to cancer care
Healthcare personnel availability
Specialized facility availability

Budget allocation to cancer care

Healthcare personnel availability

Specialized facility availability

45. A.2)Has the government announced an action plan to address the projected increase of cancer burden? *

I have read and agree to the terms of this survey and understand that my data, answers, and information will be used exclusively by AHF for the purpose of this report. *

Created at Crowdsignal.com